

ISNS biannual meeting

The sentinel Node in the era of individualized management of cancer patient

April 30th - May 2nd
Milan - Italy

Chairmen

Nicola Mozzillo & Alessandro Testori

www.isns.info



ISNS

International Sentinel Node Society

Nicola Mozzillo, MD

Director Department Melanoma
and Soft Tissue

Scientific Vice Director
Istituto Nazionale dei Tumori di Napoli

email: nimozzi@tin.it

Alessandro Testori, MD

Chairman EORTC Melanoma Group 2012-2014

Chairman chirurgia/surgical subgroup
EORTC Melanoma Group

Director
Dermato-oncological division
Istituto Europeo di Oncologia

email: alessandro.testori@ieo.it

Company Consulting srl

Piazza Cavallotti 2
00040 Castel Gandolfo (RM)
Tel. 069360565 - Mobile 339 6366072
isns.deaeventi@gmail.com





The sentinel Node in the era of individualized management of cancer patients

The International Sentinel Node Society serves and coordinates the needs of the diverse community of physicians and scientists who study the sentinel node.

It is now clear that the sentinel node concept, as originally described in patients with melanoma, is applicable to any type of malignant tumor that has the potential to spread via lymphatics to lymph nodes. Thus sentinel node technology has now entered a new phase of discovery and treatment. This technique has great potential for individualized management of solid tumors and it is also apparent that successful application of sentinel node technology requires close cooperation between dermatologists, surgeons, pathologists, radiologists and nuclear medicine physicians.

The new era of the SNB concept should be to perform this procedure both to evaluate the real necessity to perform a radical nodal dissection as it has been demonstrated for many patients with breast cancer and to drive clinicians to prescribe new adjuvant therapies with molecular based targeting or immunologically based approaches.

This medical therapies topic is becoming more and more important in the advanced disease setting, which makes the adjuvant setting the next topic to be explored and proposed for clinical research proposals.

Similarly apart the consolidated approach in melanoma and breast cancer, a clear identification of the role of SNB in most solid tumors needs to obtain a definitive validation: guide lines discussion will be conducted on all these diseases where such procedure has not reached a well defined profile and indication.

April 30

13.00 Board meeting of the steering committee

Plenary Session

16.00	Opening Ceremony Chairman N. Mozzillo, A. Testori and J. Gershenwald	
16.20	A life dedicated to conservative surgery	U. Veronesi (Milano)
16.40	Welcome message	R. Orecchia (Milano)
16.50	A tribute to Donald Morton	M. Faries (Los Angeles)
17.00	A tribute to Natale Cascinelli SNB nowadays after 20 years of history	A. Testori (Milano)
17.10	Melanoma	N. Mozzillo (Napoli)
17.20	Breast	A. Giuliano (Los Angeles)
17.55	Oral cavity	R. Martin (Auckland)
18.10	Gastro Intestinal	Y. Kitagawa (Tokyo)
18.25	Colorectal	S. Saha (Flint)
18.40	Urology	S. Horenblas (Amsterdam)
18.55	Gynecology	C. Levenback (Houston)
19.10	Assembly report	ISSN secretary J. Gershenwald (Houston)
19.30	Cocktail dinner	

May 1

Plenary Session

Sentinel Node and Technologies

Chairman E. Glass (Los Angeles)
 S. Vidal Sicart (Barcellona)

8.30 Overview of Lymphoscintigraphy
 R. Uren (Sidney)

8.45 Enhanced receptor-targeting with Tilmanocept for lymphatic mapping
 V. Sondak (Tampa)

9.00 Hybrid tracers for combined radioactivity/fluorescence detection
 F. van Leeuwen (Leiden)

9.15 Indocyanine Green for Fluorescence Imaging
 I. Stoffels (Essen)

9.30 SPECT/CT for preoperative sentinel lymph node
 localization in areas of complex anatomy.
 R. Valdés Olmos(Amsterdam/Leiden)

9.45 Sestamibi-guided biopsy of radiologically occult
 breast lesions using dedicated gamma camera devices
 L. Pereira Arias (Leiden/Leiderdorp)

10.00 Sentinel node biopsy in early stage breast cancer with a
 single incision and no lymphoscintigraphy
 M. Rizzo (Atlanta)

10.15 Confocal microscopy may help to select thin melanoma patients for SNB?
 G. Pellacani (Modena)

10.30 Discussion

10.45 Break

May 1

Plenary Session

Sentinel Node Biopsy pathologists session towards a consensus on SN sectioning

Chairman	G. Viale (Milano) C. Montesco (Padova)
11.00	Breast and melanoma
11.15	The EORTC sectioning protocol M. Cook (Guilford)
11.30	The US sectioning protocol A. Cochran (Los Angeles)
11.45	The Australian sectioning protocol R. Scolyer (Sidney)
12.00	ITC identification and biological significance in breast A. Sapino (Candiolo-Torino)
12.15	ITC identification and biological significance in melanoma H. Starz (Augsburg)
12.30	Are SN data bases comparable? A. van Akkooi (Amsterdam)
15.45	Intraoperative Frozen sectioning in breast and melanoma: PRO C. Clemente (Milano) CON A. Spatz (Montreal)
13.15	EORTC Melanoma Group slide seminar on virtual slides: challenges in the diagnosis of SN D. Massi (Firenze)
13.30	Discussion
13.45	Lunch

May 1

Room A

Microstaging and clinical decisions

- Chairman D. Massi (Firenze)
 M. Santinami (Milano)
- 14.45 Histopathology of positive SNB and long term outcome
 A. Cochran (Los Angeles)
- 15.00 Role of sentinel node in the future of cancer management
 C. Balch (Dallas)
- 15.15 Cancer metastasis from tumor microenvironment to the sentinel lymph node
 S. Leong (San Francisco)
- 15.30 SLN micrometastases as a source for mutation analysis in melanoma
 G. Botti (Napoli)
- 15.45 Molecular pathology for the analyses of melanoma SN options and pitfalls
 B. Haas (Amsterdam)
- 16.00 Should SNB be recommended?
 PRO M. Ross (Houston)
 CON D. Coit (New York)
- 16.15 Discussion
- 16.45 Break

May 1

Room A

Sentinel Node Biopsy melanoma session

Chairman N. Mozzillo (Napoli)
 A. Testori (Milano)

17.00 The role of sentinel node staging in the design
 and end results reporting of cancer clinical trial
 J. Thompson (Sidney)

17.15 SLN for atypical melanocytic neoplasms
 V. Sondak (Tampa)

17.30 Is there a good timing for SLN biopsy?
 A. Tejera-Vaquerizo (Malaga)

17.45 Management of patients with positive nodes on an ectopic
 location of the sentinel node (epitrochlear, popliteal, trunk)
 C. Caraco' (Napoli)

18.00 Role of guided FNA in diagnosis and prognosis
 O. Catalano (Napoli)

18.15 From open to minimally invasive lymphadenectomy:
 learning curve and results in quality of life
 J. Soteldo (Caracas)

18.30 Discussion

18.45 Closure

May 1

Room B

Sentinel node in lung cancer

- Chairman G. Rocco (Napoli)
 G. Veronesi (Milano)
- 14.15 Update on indications and study results
 Y. Colson (Boston)
- 14.30 Technical devices and new methods to detect SN
 I. Karo (Akita Japan)
- 14.45 Molecular patterns detectable from primary disease and SNB
 G. Caravajal (Valencia)
- 15.00 Staging pathways: SNB or imaging:
 PRO M. Alloisio (Milano)
 CON L. Spaggiari (Milano)
- 15.30 Update on immunotherapies on advanced lung cancer De Marinis (Milano)
- 15.45 Discussion
- 16.00 Break

16.15/18.00 Abstract presentations

- Chairman A. Wallace (San Diego)
 S. Lastoria (Napoli)
- 16.15 Introducing Lecture
- The treatment of peripheral advanced secondary lymphedema while the early bird catches the worm, the late riser still benefits
 C. C. Campisi (Genova)

May 2

Room A

What after positive sentinel node

Chairman F. Di Filippo (Roma)
 V. Sacchini (New York)

8.30 Value of staging imaging in melanoma patients with positive sentinel lymph nodes
 O. E. Nieweg (Sydney)

8.45 Completion lymphadenectomy after positive SLN biopsy
 Melanoma
 M. Faries (Los Angeles)

9.00 Breast
 M. Rezai (Dusseldorf)

9.15 Oral Cavity
 F. Ionna (Napoli)

9.30 Axillary management after neo adjuvant therapy in breast cancer
 A. Giuliano (Los Angeles)

9.45 Discussion

10.00 Break

May 2

Room A

What after positive sentinel node

Chairman A. Costa (Milano)
 D. D'Ugo (Roma)

10.15 Adjuvant therapies of SLN + patients: Breast
 PRO E.J.T. Rutgers (Amsterdam)
 CON M. De Laurentis (Napoli)

10.45 Adjuvant therapies of SLN + patients: Melanoma
 PRO M. Maio (Siena)
 CON A. Eggermont (Paris)

11.15 Update on immunotherapies in advanced melanoma
 P. Ascierto (Napoli)

11.30 Video assisted lymphadenectomy
 R. Rossi (Padova)

11.45 Discussion

12.00 Break

May 2

Room A

Recurrence and SNB

Chairman J. Gershenwald (Houston)
 S. Zurrida (Milano)

12.15 Follow up for morbidity and recurrence
 P. G. Gill (Adelaide)

12.30 Monitoring sentinel lymph node for circulating tumor cells (CTC)
 and cell-free circulating DNA/microRNA in melanoma patients
 D. Hoon (Santa Monica)

13.00 SNB after melanoma metastases
 J. Gershenwald (Houston)

 SNB after Breast recurrence
 J.F. Rodier (Strasbourg)

13.30 Discussion

13.45 Lunch

May 2

Room A

Sentinel node in Breast cancer

Chairman G. Ciliberto (Napoli)
 P. Veronesi (Milano)

14.30 Dedicated PET devices for breast cancer imaging and biopsy
 M. Herranz (Santiago de Compostela)

14.45 Sentinel Node Biopsy: still as a standard treatment in breast cancer surgery?
 H. Cody III (New York)

15.00 The role of SNB after neo adjuvant therapies
 V. Galimberti (Milano)

15.15 Technical devices and new methods to detect SN
 B. Ballardini (Milano)

15.30 State of the art of SN histological evaluation: still multisection analysis?
 R. Scolyer (Sidney)

15.45 Molecular biology on primary and SNB to indicate adjuvant therapies
 A. Spatz (Montreal)

16.00 Iodine 125 seed for radioguided localisation of primary lesions and lymph nodes in
breast cancer patients receiving neoadjuvant chemotherapy
 M.J. Vrancken Peeters (Amsterdam)

16.15 Towards a new era on the role of SNB in breast cancer: ongoing studies report
 O. Gentilini (Milano)

16.30 Discussion

16.45 Break

May 2

Room A

Sentinel node in H&N cancer

Chairman N. Moncrieff (Norwich)
 L. Calabrese (Milano)

17.00 Update on indications and study results
 F. Ionna (Napoli)

17.15 Technical devices and new methods to detect SN
 R. Leemans (Amsterdam)

17.30 Molecular patterns detectable from primary disease and SNB
 G. Woolgar (Liverpool)

17.45 Staging pathways: SNB or imaging
 S. Lastoria (Napoli)

18.00 Indications for medical therapy
 L. Licitra (Milano)

18.15 Discussion

18.30 Closure

May 2

Room B

Lymphoedema Following SLN biopsy and TLND

Chairman C. Campisi (Genova)
 C. Garbe (Tubingen)

8.30 Pre and post-operative evaluation of patients at risk of lymphedema
 M. Pinto (Napoli)

8.45 Diagnosis, staging and conservative treatment of
 Lymphoedema following SNB or TLND.
 S. Leong (San Francisco)

9.00 Reverse Lymphatic mapping
 S. Klimberg (Little Rock)

9.15 Lymphovascular anastomosis
 F. Boccardo (Genova)

9.30 Randomized study proposal to prevent lymphedema on groin-axillary TLND
 F. De Cian (Genova)

9.45 Lymph node transplantation
 J. H. Dayan (New York)

10.00 Discussion

10.30 Break

May 2

Room B

Sentinel node in abdominal cancer

Chairman F. Corcione (Napoli)
 M. Kitajima (Tokyo)

10.45 Technical devices and new methods
 F. Corcione (Napoli)

11.00 Update on indications and results in upper G.I.
 H. Takeuchi (Tokyo)

11.15 Update on indications and results in colon
 S. Saha (Flint)

11.30 Molecular patterns detectable from primary disease, SNB and circulating DNA
 A. Bardelli (Candiolo)

11.45 Staging pathways on laparoscopic and robotic approach
 PRO P. Bianchi (Grosseto)
 CON R. Rosati (Milano)

12.15 Indications for medical therapy
 J. Frangioni (Boston)

12.30 Discussion

13.00 Follow up randomized study on melanoma: update
 A. Testori (Milano)

13.30 Lunch

May 2

Room B

Sentinel node in gynecologic neoplasms

- Chairman S. Greggi (Napoli)
 C. Levenback (Houston)
- 14.30 Update on indications and study results
 A. van Der Zee (Groningen)
- 15.00 Technical devices and new methods to detect SN (Paramagnetic particles)
 M. Thill (Frankfurt)
- 15.15 Molecular patterns detectable from primary disease and SNB
 G. Palmieri (Sassari)
- 15.45 Staging pathways: SNB or imaging:
 PRO C. Levenback (Houston)
 CON A. Maggioni (Milano)
- 15.45 Indications for medical therapy
 N. Colombo (Milano)
- 16.00 Discussion
- 16.15 Break

May 2

Room B

Sentinel node in prostate cancer

Chairman	F. Montorsi (Milano) S. Horenblas (Amsterdam)
16.30	Update on indications and study results F. Wawroschek (Oldenburg)
16.45	Technical devices and new methods to detect SN H. G. van Der Poel (Amsterdam)
17.00	Molecular patterns detectable from primary disease (and SNB) on prostate cancer R. Montironi (Ancona)
17.15	Robotic sugery on prostate cancer+/-SNB O. De Cobelli (Milano)
17.30	Update on immunotherapies on advanced urological cancer A. Pignata (Napoli)
17.45	Discussion
18.00	Clousure

